Spain’s medical cannabis framework will finally start reaching patients over the coming days and weeks, marking a significant milestone in a four-year battle for access.
A Spanish startup has become one of only four companies authorised by Spain’s medicines regulator to cultivate medical cannabis, positioning itself to supply export markets in the UK and Germany from a pharmaceutical-grade indoor facility in the Ribera region of Burgos.
As the European medical cannabis market has developed, expanded and matured over the last half-decade, Portugal has played a critical role in the global supply chain, earning a reputation as the ‘doorway to Europe’.
Spain’s medicines agency has published the first official guidance for medical cannabis preparations, confirming that its incoming market will exclude raw cannabis flower in favour of ‘standardised’ oral solutions prepared exclusively in hospital pharmacies.
Spain represents one of the most exciting incoming additions to the European medical cannabis market this year, as one of the continent’s largest producers finally moves toward domestic patient access after years of hard-fought advocacy.
First published on Cannabis Health In a landmark decision, Spain’s Council of Ministers has approved a Royal Decree regulating the medical use of cannabis-based preparations in hospital settings, marking the country’s first comprehensive framework for cannabis-derived medicines.
New data acquired from the Home Office by Prohibition Partners and Business of Cannabis shows that since 2021, the UK has imported the bulk of its medical cannabis from Spain.
Spain’s long-awaited medical cannabis program has finally taken a step forward as a draft of a Royal Decree has been sent to the European Union for approval.
Spain’s long-awaited and hard-fought legislation to launch a medical cannabis market in the country has been slammed by pharmacists, patient advocacy groups and cannabis businesses.
